Forever Health

Introduction

For years, drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) were celebrated almost exclusively for weight loss. But a wave of research — including a landmark study published just days ago — is reframing how scientists think about this entire drug class. GLP-1 receptor agonists, it turns out, may be among the most brain-active medications we have ever encountered.

A major study released March 22, 2026 found that people taking semaglutide experienced a 42% lower risk of worsening mental illness during treatment compared to periods off the drug. Depression risk fell by 44%, anxiety disorders dropped by 38%, psychiatric hospitalizations plunged by 42%, and substance use disorders were 47% lower during active treatment.

These are not minor statistical blips. They represent a potential paradigm shift in mental health treatment. This post breaks down what leading experts are saying, the neuroscience behind these findings, and what you need to know before considering these medications.

What the Experts Are Saying

Neuroscientist Dr. Andrew Huberman, in his podcast featuring UCSF neuroscientist Dr. Zachary Knight, explains that GLP-1 drugs like semaglutide amplify the body’s natural GLP-1 hormone signaling by as much as 10,000-fold. This pharmacological boost acts not just on gut receptors but directly on brainstem neurons — and, critically, on the mesolimbic reward system and hippocampus — structures governing mood, memory, and addiction.

Dr. Rhonda Patrick, biomedical scientist and founder of FoundMyFitness, has highlighted the emerging neuroprotective data: “Medications like semaglutide are gaining attention not only for their metabolic benefits but also for potential neuroprotective effects. Recent studies suggest they may reduce dementia risk by up to 33% in individuals with type 2 diabetes.” Patrick has also noted the growing interest in micro-dosing GLP-1 agonists, arguing that lower doses may deliver meaningful mood and cognitive benefits while minimizing side effects.

Dr. Peter Attia, longevity physician and host of The Drive podcast, has covered GLP-1s extensively in his AMA series. While enthusiastic about their metabolic and cardiovascular benefits, Attia consistently cautions that lean muscle preservation is paramount — these drugs must be used alongside resistance training and adequate protein intake. His framing — that GLP-1s are powerful tools but not silver bullets — is an important counterbalance to the hype.

Dr. Mark Hyman, functional medicine physician, has described GLP-1s as a genuine metabolic revolution, while urging that they be integrated into a broader lifestyle strategy. “A holistic approach that includes diet, lifestyle, and personalized interventions is essential for sustainable health improvements,” Hyman notes.

The Science Behind It

GLP-1 (glucagon-like peptide-1) is a hormone naturally released by the gut after eating. Its primary job is to signal the pancreas to release insulin, suppress glucagon, and tell the brain that the body has been fed. However, GLP-1 receptors are distributed throughout the central nervous system, including the hippocampus (learning and memory), the ventral tegmental area, and the nucleus accumbens — the very heart of the brain’s dopamine reward circuitry.

When GLP-1 receptors are activated in the reward system, dopamine release is modulated, which researchers believe is responsible for the dramatic reductions in addictive cravings seen in clinical studies. A randomized controlled trial published in February 2025 found that people with alcohol use disorder who took low-dose semaglutide had significantly fewer heavy drinking days and fewer cravings compared to placebo. Similar reductions have been observed for opioid and nicotine dependence.

GLP-1 drugs also appear to reduce neuroinflammation, support cerebral blood flow, and may even protect against amyloid plaque accumulation — a hallmark of Alzheimer’s disease. The ELAD trial, studying liraglutide (an earlier GLP-1 agonist) in patients with early Alzheimer’s, found that the drug slowed cognitive decline by 18% and reduced brain shrinkage by 50% over 12 months. In January 2026, the FDA removed suicidal behavior and ideation warnings from certain GLP-1 medications after a comprehensive review of over 100,000 patients found no increased risk.

Key Benefits

• Depression reduction: Semaglutide use has been associated with a 44% lower risk of worsening depression symptoms in large-scale real-world studies, with effects potentially driven by anti-inflammatory, dopaminergic, and neurogenic mechanisms.
• Anxiety relief: GLP-1 treatment is linked to a 38% reduction in anxiety disorder worsening, possibly through modulation of the hypothalamic-pituitary-adrenal (HPA) stress axis and reduced systemic inflammation.
• Addiction dampening: GLP-1 drugs reduce cravings and use of alcohol, opioids, nicotine, and stimulants by acting on the brain’s dopamine reward circuitry — the same circuits hijacked by addictive substances.
• Cognitive and memory support: GLP-1 receptor activation in the hippocampus promotes the growth and survival of new neurons, supporting learning, memory, and resilience against dementia.
• Neuroprotection: Evidence from clinical trials suggests GLP-1 agonists may slow neurodegeneration, with studies showing up to 33% reduced dementia risk in diabetic populations.
• Reduced psychiatric hospitalization: Real-world data shows psychiatric hospital admissions and sick days related to mental illness fell by 42% during semaglutide treatment periods.

How to Get Started

If you are interested in exploring GLP-1 receptor agonists — whether for metabolic, psychiatric, or neurological reasons — start with a conversation with a qualified physician. GLP-1 medications are FDA-approved for type 2 diabetes and chronic weight management; prescribing for mental health indications is currently off-label.

If you begin one of these medications, Dr. Peter Attia strongly recommends pairing it with a resistance training program and at least 1.6g of protein per kg of body weight daily to protect lean muscle mass. Dr. Rhonda Patrick suggests discussing lower “micro-doses” with your doctor, as emerging data suggests meaningful benefit at doses below the standard titration. Keeping a simple journal of mood, sleep, and energy changes helps you and your doctor track both metabolic and mental health progress.

What to Watch Out For

Despite the exciting new data, caution is warranted. The mental health evidence remains largely observational, and randomized trials targeting depression and anxiety with GLP-1 drugs are still in early stages. Some patients — particularly those with a genetic predisposition to low dopamine function — may experience emotional blunting or worsened mood. Individual responses vary considerably.

Common side effects include nausea, constipation, and fatigue, especially during dose escalation. GLP-1 drugs are not appropriate for individuals with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2. Pregnant or breastfeeding women should avoid them. Anyone with a pre-existing psychiatric diagnosis should work closely with both a psychiatrist and a prescribing physician, as interactions with psychotropic medications are not yet well characterized.

Watch the Full Expert Videos

Andrew Huberman & Dr. Zachary Knight (Huberman Lab): How Do Ozempic, Mounjaro & Other GLP-1 Agonists Work? — The Science of Hunger & Medications to Combat Obesity

GLP-1 Deep Dive (Science & Hacks): GLP-1, Ozempic: The Science and Hacks You Must Know

Dr. Rhonda Patrick (FoundMyFitness): Is Ozempic a Miracle Drug for Weight Loss? — FoundMyFitness YouTube Channel

Peter Attia (The Drive Podcast): AMA #64: New Insights on GLP-1 Agonists — The Peter Attia Drive YouTube Channel